The shared genetic hallmark of neurocutaneous syndromes lies in somatic mutations disrupting core developmental pathways—including mTOR, Ras-MAPK, and Gαq-PLCβ signaling—leading to pluripotent progenitor cell dysregulation, tissue malformations, and tumorigenesis (32). This evidence concerns the gene MTOR and neurocutaneous syndrome.